Yoshiaki Kuroda

579 total citations
36 papers, 403 citations indexed

About

Yoshiaki Kuroda is a scholar working on Hematology, Oncology and Molecular Biology. According to data from OpenAlex, Yoshiaki Kuroda has authored 36 papers receiving a total of 403 indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Hematology, 21 papers in Oncology and 18 papers in Molecular Biology. Recurrent topics in Yoshiaki Kuroda's work include Multiple Myeloma Research and Treatments (22 papers), Peptidase Inhibition and Analysis (10 papers) and Protein Degradation and Inhibitors (9 papers). Yoshiaki Kuroda is often cited by papers focused on Multiple Myeloma Research and Treatments (22 papers), Peptidase Inhibition and Analysis (10 papers) and Protein Degradation and Inhibitors (9 papers). Yoshiaki Kuroda collaborates with scholars based in Japan, United States and Greece. Yoshiaki Kuroda's co-authors include Akira Sakai, Jiro Kikuchi, Hideki Asaoku, Yusuke Furukawa, Daisuke Koyama, Akiro Kimura, Yuta Katayama, Tohru Izumi, Hiroshi Yasui and Shotaro Hagiwara and has published in prestigious journals such as Blood, PLoS ONE and Cancer Research.

In The Last Decade

Yoshiaki Kuroda

35 papers receiving 399 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Yoshiaki Kuroda Japan 12 222 204 161 71 51 36 403
Donald Gravenor United States 9 98 0.4× 150 0.7× 214 1.3× 174 2.5× 20 0.4× 24 433
Asaka Kondo Japan 6 208 0.9× 113 0.6× 261 1.6× 242 3.4× 34 0.7× 8 435
Line Nederby Denmark 12 204 0.9× 147 0.7× 121 0.8× 145 2.0× 81 1.6× 42 445
Connie Qi Canada 8 269 1.2× 236 1.2× 137 0.9× 26 0.4× 76 1.5× 14 350
Luca De Rosa Italy 10 324 1.5× 226 1.1× 234 1.5× 76 1.1× 37 0.7× 31 448
Sara Pepe Italy 9 77 0.3× 162 0.8× 97 0.6× 74 1.0× 104 2.0× 35 366
Hideaki Sakabe Japan 7 173 0.8× 269 1.3× 159 1.0× 133 1.9× 54 1.1× 10 473
D Borrego Spain 7 342 1.5× 186 0.9× 155 1.0× 60 0.8× 105 2.1× 11 414
Friederike Schneider Germany 10 388 1.7× 331 1.6× 145 0.9× 44 0.6× 175 3.4× 16 662
A Jacobs United Kingdom 7 240 1.1× 158 0.8× 120 0.7× 92 1.3× 97 1.9× 12 421

Countries citing papers authored by Yoshiaki Kuroda

Since Specialization
Citations

This map shows the geographic impact of Yoshiaki Kuroda's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yoshiaki Kuroda with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yoshiaki Kuroda more than expected).

Fields of papers citing papers by Yoshiaki Kuroda

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yoshiaki Kuroda. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yoshiaki Kuroda. The network helps show where Yoshiaki Kuroda may publish in the future.

Co-authorship network of co-authors of Yoshiaki Kuroda

This figure shows the co-authorship network connecting the top 25 collaborators of Yoshiaki Kuroda. A scholar is included among the top collaborators of Yoshiaki Kuroda based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yoshiaki Kuroda. Yoshiaki Kuroda is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Terao, Toshiki, et al.. (2024). Discrepancy of Hans’ criteria for clonally related nodal and pericardiac fluid diffuse large B-cell lymphoma with <i>MYD88</i> L265P mutation. Journal of Clinical and Experimental Hematopathology. 64(4). 318–322. 1 indexed citations
2.
Ishida, Tadao, Yoshiaki Kuroda, Takuya Komeno, et al.. (2024). A Phase 1/2 study of teclistamab, a humanized BCMA × CD3 bispecific Ab in Japanese patients with relapsed/refractory MM. International Journal of Hematology. 121(2). 222–231. 2 indexed citations
3.
Martin, Thomas G., María-Victoria Mateos, Niels W.C.J. van de Donk, et al.. (2024). Pooled Efficacy and Safety of Teclistamab in 217 Patients with Triple-Class Exposed Relapsed/Refractory Multiple Myeloma from 3 Registrational Clinical Studies. Blood. 144(Supplement 1). 3331–3331.
4.
Souri, Masayoshi, et al.. (2023). [Autoimmune acquired coagulation factor XIII/13 deficiency caused by type Ab anti-FXIII-A autoantibody].. PubMed. 64(12). 1508–1513. 1 indexed citations
5.
Kikuchi, Jiro, Sho Ikeda, Takahiro Kobayashi, et al.. (2022). EMD originates from hyaluronan-induced homophilic interactions of CD44 variant-expressing MM cells under shear stress. Blood Advances. 7(4). 508–524. 5 indexed citations
6.
Kuroda, Yoshiaki, Daisuke Koyama, Jiro Kikuchi, et al.. (2021). Autophagic degradation of NOXA underlies stromal cell-mediated resistance to proteasome inhibitors in mantle cell lymphoma. Leukemia Research. 111. 106672–106672. 3 indexed citations
7.
Koyama, Daisuke, Jiro Kikuchi, Yoshiaki Kuroda, Masatsugu Ohta, & Yusuke Furukawa. (2020). AMP‐activated protein kinase activation primes cytoplasmic translocation and autophagic degradation of the BCR‐ABL protein in CML cells. Cancer Science. 112(1). 194–204. 12 indexed citations
8.
Kuroda, Yoshiaki, et al.. (2020). Successful treatment with gilteritinib for isolated extramedullary relapse of acute myeloid leukemia with FLT3-ITD mutation after allogeneic stem cell transplantation. International Journal of Hematology. 112(2). 243–248. 14 indexed citations
9.
Ozaki, Shuji, Hiroshi Handa, Takayuki Saitoh, et al.. (2019). Evaluation of the Revised International Staging System (R-ISS) in Japanese patients with multiple myeloma. Annals of Hematology. 98(7). 1703–1711. 9 indexed citations
10.
Kikuchi, Jiro, Yoshiaki Kuroda, Daisuke Koyama, et al.. (2018). Myeloma Cells Are Activated in Bone Marrow Microenvironment by the CD180/MD-1 Complex, Which Senses Lipopolysaccharide. Cancer Research. 78(7). 1766–1778. 21 indexed citations
11.
Igarashi, Tadahiko, Michinori Ogura, Kuniaki Itoh, et al.. (2016). Japanese phase II study of rituximab maintenance for untreated indolent B-cell non-Hodgkin lymphoma with high tumor burden. International Journal of Hematology. 104(6). 700–708. 5 indexed citations
12.
Mu, Song, Yoshiaki Kuroda, Hirohiko Shibayama, et al.. (2015). Panobinostat PK/PD profile in combination with bortezomib and dexamethasone in patients with relapsed and relapsed/refractory multiple myeloma. European Journal of Clinical Pharmacology. 72(2). 153–161. 21 indexed citations
13.
Kaichi, Yoko, Shuji Date, Yuji Akiyama, et al.. (2015). Iterative Decomposition of Water and Fat with Echo Asymmetry and Least-Squares Estimation (IDEAL) Magnetic Resonance Imaging as a Biomarker for Symptomatic Multiple Myeloma. PLoS ONE. 10(2). e0116842–e0116842. 29 indexed citations
14.
Tamura, Takayuki, Yoko Kaichi, Yuji Akiyama, et al.. (2014). Magnetic Resonance Evaluation of Multiple Myeloma at 3.0 Tesla: How Do Bone Marrow Plasma Cell Percentage and Selection of Protocols Affect Lesion Conspicuity?. PLoS ONE. 9(1). e85931–e85931. 3 indexed citations
15.
Yoshida, Noriaki, Yoshiaki Kuroda, Yuta Katayama, et al.. (2013). Clinical Significance of sIL-2R Levels in B-Cell Lymphomas. PLoS ONE. 8(11). e78730–e78730. 46 indexed citations
16.
Harada, Takeshi, Shuji Ozaki, Asuka Oda, et al.. (2013). Combination with a Defucosylated Anti-HM1.24 Monoclonal Antibody plus Lenalidomide Induces Marked ADCC against Myeloma Cells and Their Progenitors. PLoS ONE. 8(12). e83905–e83905. 13 indexed citations
17.
Kaichi, Yoko, et al.. (2013). Vertebral Fracture Risk of Multiple Myeloma Assessed by a CT-based Finite Element and Trabecular Structure Analysis. Clinical Lymphoma Myeloma & Leukemia. 14(1). 12–13. 3 indexed citations
18.
Sakai, Akira, Yoshiaki Kuroda, Yuta Katayama, et al.. (2007). Connective tissue growth factor is an indicator of bone involvement in multiple myeloma, but matrix metalloproteinase‐9 is not. British Journal of Haematology. 139(1). 41–50. 14 indexed citations
19.
20.
Sakai, Akira, Y Takimoto, Jun Imagawa, et al.. (2004). Progressive Myeloma after Thalidomide Therapy in a Patient with Immature Phenotype of Myeloma (Plasma) Cells. International Journal of Hematology. 79(4). 364–368. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Donald Gravenor Breakdown of academic impact, for papers by Asaka Kondo Breakdown of academic impact, for papers by Line Nederby Breakdown of academic impact, for papers by Connie Qi Breakdown of academic impact, for papers by Luca De Rosa Breakdown of academic impact, for papers by Sara Pepe Breakdown of academic impact, for papers by Hideaki Sakabe Breakdown of academic impact, for papers by D Borrego Breakdown of academic impact, for papers by Friederike Schneider Breakdown of academic impact, for papers by A Jacobs
Rankless by CCL
2026